{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T20:03:18Z","timestamp":1787169798892,"version":"build-2736575974"},"reference-count":81,"publisher":"Deutscher Arzte-Verlag GmbH","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"DOI":"10.3238\/arztebl.m2026.0046","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:21:07Z","timestamp":1781072467000},"source":"Crossref","is-referenced-by-count":1,"title":["Tranexamic acid for acute bleeding in severely traumatized patients: Mortality, neurological outcomes, and thromboembolic risk"],"prefix":"10.3238","author":[{"given":"Heiko","family":"Lier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Maegele","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bj\u00f6rn","family":"Hossfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"11437","published-online":{"date-parts":[[2026,6,12]]},"reference":[{"key":"10.3238\/arztebl.m2026.0046_ref1","doi-asserted-by":"crossref","unstructured":"El-Menyar A, Ahmed K, Hakim S, et al.: Efficacy and safety of the second in-hospital dose of tranexamic acid after receiving the prehospital dose: Double-blind randomized controlled clinical trial in a level 1 trauma center. Eur J Trauma Emerg Surg 2022; 48: 3089\u201399","DOI":"10.1007\/s00068-021-01848-0"},{"key":"10.3238\/arztebl.m2026.0046_ref2","doi-asserted-by":"crossref","unstructured":"PATCH-Trauma Investigators, ANZICS Clinical Trials Group, Gruen RL, et al.: Prehospital tranexamic acid for severe trauma. N Engl J Med 2023; 389: 127\u201336","DOI":"10.1056\/NEJMoa2215457"},{"key":"10.3238\/arztebl.m2026.0046_ref3","doi-asserted-by":"crossref","unstructured":"Yassi N, Zhao H, Churilov L, et al.: Tranexamic acid versus placebo in individuals with intracerebral haemorrhage treated within 2 h of symptom onset (STOP-MSU): An international, double-blind, randomised, phase 2 trial. Lancet Neurol 2024; 23: 577\u201387","DOI":"10.1016\/S1474-4422(24)00128-5"},{"key":"10.3238\/arztebl.m2026.0046_ref4","doi-asserted-by":"crossref","unstructured":"Knudson MM, Moore EE, Kornblith LZ, et al.: Challenging traditional paradigms in posttraumatic pulmonary thromboembolism. JAMA Surg 2022; 157: e216356","DOI":"10.1001\/jamasurg.2021.6356"},{"key":"10.3238\/arztebl.m2026.0046_ref5","doi-asserted-by":"crossref","unstructured":"van Wessem KJP, Jochems D, Leenen LPH: The effect of prehospital tranexamic acid on outcome in polytrauma patients with associated severe brain injury. Eur J Trauma Emerg Surg 2022; 48: 1589\u201399","DOI":"10.1007\/s00068-021-01827-5"},{"key":"10.3238\/arztebl.m2026.0046_ref6","doi-asserted-by":"crossref","unstructured":"Bayer J, Kirchner T, Lefering R, Bode L, Schmal H, Wagner FC: Tranexamic acid in multiply injured patients-the independent risk of thromboembolic complications with repeated dosing: Retrospective analysis based on the TraumaRegister DGU\u00ae. Scand J Trauma Resusc Emerg Med 2025; 33: 185","DOI":"10.1186\/s13049-025-01512-1"},{"key":"10.3238\/arztebl.m2026.0046_ref7","doi-asserted-by":"crossref","unstructured":"Ageron FX, Shakur-Still H, Roberts I: Effects of tranexamic acid treatment in severely and non-severely injured trauma patients. Transfusion 2022; 62 Suppl 1: S151\u2013S7","DOI":"10.1111\/trf.16954"},{"key":"10.3238\/arztebl.m2026.0046_ref8","doi-asserted-by":"crossref","unstructured":"Spinella PC, Bochicchio K, Thomas KA, et al.: The risk of thromboembolic events with early intravenous 2\u2013 and 4-g bolus dosing of tranexamic acid compared to placebo in patients with severe traumatic bleeding: A secondary analysis of a randomized, double-blind, placebo-controlled, single-center trial. Transfusion 2022; 62 Suppl 1: S139\u2013S50","DOI":"10.1111\/trf.16962"},{"key":"10.3238\/arztebl.m2026.0046_ref9","doi-asserted-by":"crossref","unstructured":"Deeb AP, Guyette FX, Daley BJ, et al.: Time to early resuscitative intervention association with mortality in trauma patients at risk for hemorrhage. J Trauma Acute Care Surg 2023; 94: 504\u201312","DOI":"10.1097\/TA.0000000000003820"},{"key":"10.3238\/arztebl.m2026.0046_ref10","doi-asserted-by":"crossref","unstructured":"Gunn F, Stevenson R, Almuwallad A, et al.: A comparative analysis of tranexamic acid dosing strategies in traumatic major hemorrhage. J Trauma Acute Care Surg 2024; 96: 216\u201324","DOI":"10.1097\/TA.0000000000004177"},{"key":"10.3238\/arztebl.m2026.0046_ref11","doi-asserted-by":"crossref","unstructured":"Mazzei M, Donohue JK, Schreiber M, et al.: Prehospital tranexamic acid is associated with a survival benefit without an increase in complications: Results of two harmonized randomized clinical trials. J Trauma Acute Care Surg 2024; 97: 697\u2013702","DOI":"10.1097\/TA.0000000000004315"},{"key":"10.3238\/arztebl.m2026.0046_ref12","doi-asserted-by":"crossref","unstructured":"Rowell S, Meier EN, Hoyos Gomez T, et al.: The effects of prehospital TXA on mortality and neurologic outcomes in patients with traumatic intracranial hemorrhage: A subgroup analysis from the prehospital TXA for TBI trial. J Trauma Acute Care Surg 2024; 97: 572\u201380","DOI":"10.1097\/TA.0000000000004354"},{"key":"10.3238\/arztebl.m2026.0046_ref13","doi-asserted-by":"crossref","unstructured":"Osawa I, Goto T, Roberts I: Tranexamic acid for trauma: Optimal timing of administration based on the CRASH-2 and CRASH-3 trials. Br J Surg 2025; 112: znaf079","DOI":"10.1093\/bjs\/znaf079"},{"key":"10.3238\/arztebl.m2026.0046_ref14","doi-asserted-by":"crossref","unstructured":"Ali A, Gruen RL, Bernard SA, et al.: Tranexamic acid timing and mortality impact after trauma. Ann Emerg Med 2026; 87: 83\u20139","DOI":"10.1016\/j.annemergmed.2025.06.609"},{"key":"10.3238\/arztebl.m2026.0046_ref15","doi-asserted-by":"crossref","unstructured":"Huang H, Xin M, Wu X, et al.: The efficacy of tranexamic acid treatment with different time and doses for traumatic brain injury: A systematic review and meta-analysis. Thromb J 2022; 20: 79","DOI":"10.1186\/s12959-022-00440-9"},{"key":"10.3238\/arztebl.m2026.0046_ref16","doi-asserted-by":"crossref","unstructured":"Germans MR, Dronkers WJ, Baharoglu MI, et al.: Antifibrinolytic therapy for aneurysmal subarachnoid hemorrhage: An update of a Cochrane systematic review. Stroke 2023; 54: e91\u2013e2","DOI":"10.1161\/STROKEAHA.122.041955"},{"key":"10.3238\/arztebl.m2026.0046_ref17","doi-asserted-by":"crossref","unstructured":"Xiong Y, Guo X, Huang X, et al.: Efficacy and safety of tranexamic acid in intracranial haemorrhage: A meta-analysis. PLoS One 2023; 18: e0282726","DOI":"10.1371\/journal.pone.0282726"},{"key":"10.3238\/arztebl.m2026.0046_ref18","doi-asserted-by":"crossref","unstructured":"Biffi A, Porcu G, Castellini G, et al.: Systemic hemostatic agents initiated in trauma patients in the pre-hospital setting: A systematic review. Eur J Trauma Emerg Surg 2023; 49: 1259\u201370","DOI":"10.1007\/s00068-022-02185-6"},{"key":"10.3238\/arztebl.m2026.0046_ref19","doi-asserted-by":"crossref","unstructured":"Acharya P, Amin A, Nallamotu S, et al.: Prehospital tranexamic acid in trauma patients: A systematic review and meta-analysis of randomized controlled trials. Front Med (Lausanne) 2023; 10: 1284016","DOI":"10.3389\/fmed.2023.1284016"},{"key":"10.3238\/arztebl.m2026.0046_ref20","doi-asserted-by":"crossref","unstructured":"Song JX, Wu JX, Zhong H, Chen W, Zheng JC: Therapeutic efficacy of tranexamic acid on traumatic brain injury: A systematic review and meta-analysis. Scand J Trauma Resusc Emerg Med 2024; 32: 18","DOI":"10.1186\/s13049-024-01188-z"},{"key":"10.3238\/arztebl.m2026.0046_ref21","doi-asserted-by":"crossref","unstructured":"Fouche PF, Stein C, Nichols M, et al.: Tranexamic acid for traumatic injury in the emergency setting: A systematic review and bias-adjusted meta-analysis of randomized controlled trials. Ann Emerg Med 2024; 83: 435\u201345","DOI":"10.1016\/j.annemergmed.2023.10.004"},{"key":"10.3238\/arztebl.m2026.0046_ref22","doi-asserted-by":"crossref","unstructured":"Zhang M, Liu T: Efficacy and safety of tranexamic acid in acute traumatic brain injury: A meta-analysis of randomized controlled trials. Am J Emerg Med 2024; 80: 35\u201343","DOI":"10.1016\/j.ajem.2024.03.005"},{"key":"10.3238\/arztebl.m2026.0046_ref23","doi-asserted-by":"crossref","unstructured":"Tran A, Fernando SM, Rochwerg B, et al.: Prognostic factors associated with venous thromboembolism following traumatic injury: A systematic review and meta-analysis. J Trauma Acute Care Surg 2024; 97: 471\u20137","DOI":"10.1097\/TA.0000000000004326"},{"key":"10.3238\/arztebl.m2026.0046_ref24","doi-asserted-by":"crossref","unstructured":"Chen HY, Wu LG, Fan CC, Yuan W, Xu WT: Effectiveness and safety of prehospital tranexamic acid in patients with trauma: An updated systematic review and meta-analysis with trial sequential analysis. BMC Emerg Med 2024; 24: 202","DOI":"10.1186\/s12873-024-01119-2"},{"key":"10.3238\/arztebl.m2026.0046_ref25","doi-asserted-by":"crossref","unstructured":"Li Y, Tian M, Zhong W, Zou J, Duan X, Si H: Prehospital tranexamic acid decreases early mortality in trauma patients: A systematic review and meta-analysis. Front Med (Lausanne) 2025; 12: 1552271","DOI":"10.3389\/fmed.2025.1552271"},{"key":"10.3238\/arztebl.m2026.0046_ref26","doi-asserted-by":"crossref","unstructured":"Lee S, Kim M, Kwon SM, et al.: Relationship between tranexamic acid use and safety in patients with acute brain injury: A systematic review and meta-analysis of mortality and thromboembolic events. CNS Drugs 2025; 39: 637\u201350","DOI":"10.1007\/s40263-025-01185-5"},{"key":"10.3238\/arztebl.m2026.0046_ref27","doi-asserted-by":"crossref","unstructured":"Utsumi S, Kawakami A, Amemiya Y: Optimal dose of tranexamic acid in traumatic brain injury: Systematic review and network meta-analysis of randomized controlled trials. J Trauma Acute Care Surg 2025; 98: 816\u201323","DOI":"10.1097\/TA.0000000000004500"},{"key":"10.3238\/arztebl.m2026.0046_ref28","doi-asserted-by":"crossref","unstructured":"Steiner T, Purrucker JC, Aguiar de Sousa D, et al.: European Stroke Organisation (ESO) and European Association of Neurosurgical Societies (EANS) guideline on stroke due to spontaneous intracerebral haemorrhage. Eur Stroke J 2025; 10: 1007\u201386","DOI":"10.1177\/23969873251340815"},{"key":"10.3238\/arztebl.m2026.0046_ref29","doi-asserted-by":"crossref","unstructured":"Lin YC, Wang TH, Kang YN, Chiu HH: Effect of tranexamic acid on children with traumatic bleeding: A systematic review and meta-analysis. Am J Emerg Med 2025; 97: 65\u201371","DOI":"10.1016\/j.ajem.2025.07.008"},{"key":"10.3238\/arztebl.m2026.0046_ref30","doi-asserted-by":"crossref","unstructured":"Bian W, Qi M, Ding L, et al.: Is tranexamic acid effective for all traumatic brain injury patients? A severity based systematic review and meta-analysis. Front Pharmacol 2025; 16: 1677936","DOI":"10.3389\/fphar.2025.1677936"},{"key":"10.3238\/arztebl.m2026.0046_ref31","unstructured":"Deutsche Gesellschaft f\u00fcr Unfallchirurgie (DGU): TraumaRegister DGU Jahresbericht 2025. www.auc-online.de\/fileadmin\/AUC\/Dokumente\/Register\/TraumaRegister_DGU\/TR-DGU-Jahresbericht_2025.pdf (last accessed on 3 February 2026)."},{"key":"10.3238\/arztebl.m2026.0046_ref32","doi-asserted-by":"crossref","unstructured":"CRASH-2 Trial Collaborators, Shakur H, Roberts I, et al.: Effects of tranexamic acid on death, vascular occlusive events, and blood transfusion in trauma patients with significant haemorrhage (CRASH-2): A randomised, placebo-controlled trial. Lancet 2010; 376: 23\u201332","DOI":"10.1016\/S0140-6736(10)60835-5"},{"key":"10.3238\/arztebl.m2026.0046_ref33","doi-asserted-by":"crossref","unstructured":"CRASH-3 Trial Collaborators, Roberts I, Shakur-Still H, et al.: Effects of tranexamic acid on death, disability, vascular occlusive events and other morbidities in patients with acute traumatic brain injury (CRASH-3): A randomised, placebo-controlled trial. Lancet 2019; 394: 1713\u201323","DOI":"10.1016\/S0140-6736(19)32233-0"},{"key":"10.3238\/arztebl.m2026.0046_ref34","unstructured":"Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V.: AWMF-Leitlinie 187\u2013023: S3-Leitlinie Polytrauma\/Schwerverletzten-Behandlung. https:\/\/register.awmf.org\/assets\/guidelines\/187-023l_S3_Polytrauma-Schwerverletzten-Behandlung_2023-06.pdf (last accessed on 14 February 2023)."},{"key":"10.3238\/arztebl.m2026.0046_ref35","doi-asserted-by":"crossref","unstructured":"Takahashi K, Yamakawa K, Siletz AE, et al.: Hyperfibrinolysis: A crucial phenotypic abnormality of posttraumatic fibrinolytic dysfunction. Res Pract Thromb Haemost 2024; 8: 102568","DOI":"10.1016\/j.rpth.2024.102568"},{"key":"10.3238\/arztebl.m2026.0046_ref36","doi-asserted-by":"crossref","unstructured":"Chalkias A: Shear stress and endothelial mechanotransduction in trauma patients with hemorrhagic shock: Hidden coagulopathy pathways and novel therapeutic strategies. Int J Mol Sci 2023; 24: 17522","DOI":"10.3390\/ijms242417522"},{"key":"10.3238\/arztebl.m2026.0046_ref37","doi-asserted-by":"crossref","unstructured":"Moore HB, Moore EE, Gonzalez E, et al.: Hyperfibrinolysis, physiologic fibrinolysis, and fibrinolysis shutdown: The spectrum of postinjury fibrinolysis and relevance to antifibrinolytic therapy. J Trauma Acute Care Surg 2014; 77: 811\u20137","DOI":"10.1097\/TA.0000000000000341"},{"key":"10.3238\/arztebl.m2026.0046_ref38","doi-asserted-by":"crossref","unstructured":"Moore HB: Fibrinolysis shutdown and hypofibrinolysis are not synonymous terms: The clinical significance of differentiating low fibrinolytic states. Semin Thromb Hemost 2023; 49: 433\u201343","DOI":"10.1055\/s-0042-1758057"},{"key":"10.3238\/arztebl.m2026.0046_ref39","unstructured":"Rote Liste Fachinformation: Cyklokapron-Injektionsl\u00f6sung (Feb 2025). https:\/\/www.fachinfo.de\/fi\/detail\/008797 (last accessed on 12 April 2025)."},{"key":"10.3238\/arztebl.m2026.0046_ref40","doi-asserted-by":"crossref","unstructured":"Grassin-Delyle S, Semeraro M, Lamy E, et al.: Pharmacokinetics of tranexamic acid after intravenous, intramuscular, and oral routes: A prospective, randomised, crossover trial in healthy volunteers. Br J Anaesth 2022; 128: 465\u201372","DOI":"10.1016\/j.bja.2021.10.054"},{"key":"10.3238\/arztebl.m2026.0046_ref41","doi-asserted-by":"crossref","unstructured":"Faraoni D, Fenger-Eriksen C: Dosing of tranexamic acid in trauma. Curr Opin Anaesthesiol 2024; 37: 125\u201330","DOI":"10.1097\/ACO.0000000000001357"},{"key":"10.3238\/arztebl.m2026.0046_ref42","doi-asserted-by":"crossref","unstructured":"Yoshii R, Takahashi Y, Sawa T, Amaya F, Ogawa S: Long duration of action of tranexamic acid after cardiac surgery in a hemodialysis patient: A case report. A A Pract 2023; 17: e01676","DOI":"10.1213\/XAA.0000000000001676"},{"key":"10.3238\/arztebl.m2026.0046_ref43","doi-asserted-by":"crossref","unstructured":"Kammerer T, Groene P, Sappel SR, et al.: Functional testing for tranexamic acid duration of action using modified viscoelastometry. Transfus Med Hemother 2021; 48: 109\u201317","DOI":"10.1159\/000511230"},{"key":"10.3238\/arztebl.m2026.0046_ref44","doi-asserted-by":"crossref","unstructured":"Guyette FX, Brown JB, Zenati MS, et al.: Tranexamic acid during prehospital transport in patients at risk for hemorrhage after injury: A double-blind, placebo-controlled, randomized clinical Trial. JAMA Surg 2020; 156: 11\u201320","DOI":"10.1001\/jamasurg.2020.4350"},{"key":"10.3238\/arztebl.m2026.0046_ref45","doi-asserted-by":"crossref","unstructured":"Neeki MM, Dong F, Toy J, et al.: Tranexamic acid in civilian trauma care in the California prehospital antifibrinolytic therapy study. West J Emerg Med 2018; 19: 977\u201386","DOI":"10.5811\/westjem.2018.8.39336"},{"key":"10.3238\/arztebl.m2026.0046_ref46","doi-asserted-by":"crossref","unstructured":"Morrison JJ, Dubose JJ, Rasmussen TE, Midwinter MJ: Military application of tranexamic acid in trauma emergency resuscitation (MATTERs) Study. Arch Surg 2012; 147: 113\u20139","DOI":"10.1001\/archsurg.2011.287"},{"key":"10.3238\/arztebl.m2026.0046_ref47","doi-asserted-by":"crossref","unstructured":"Cole E, Davenport R, Willett K, Brohi K: Tranexamic acid use in severely injured civilian patients and the effects on outcomes: A prospective cohort study. Ann Surg 2015; 261: 390\u20134","DOI":"10.1097\/SLA.0000000000000717"},{"key":"10.3238\/arztebl.m2026.0046_ref48","doi-asserted-by":"crossref","unstructured":"Rossetto A, Vulliamy P, Lee KM, Brohi K, Davenport R: Temporal transitions in fibrinolysis after trauma: Adverse outcome is principally related to late hypofibrinolysis. Anesthesiology 2022; 136: 148\u201361","DOI":"10.1097\/ALN.0000000000004036"},{"key":"10.3238\/arztebl.m2026.0046_ref49","doi-asserted-by":"crossref","unstructured":"Moore HB, Moore EE, Huebner BR, et al.: Tranexamic acid is associated with increased mortality in patients with physiological fibrinolysis. J Surg Res 2017; 220: 438\u201343","DOI":"10.1016\/j.jss.2017.04.028"},{"key":"10.3238\/arztebl.m2026.0046_ref50","doi-asserted-by":"crossref","unstructured":"Patel PA, Wyrobek JA, Butwick AJ, et al.: Update on applications and limitations of perioperative tranexamic acid. Anesth Analg 2022; 135: 460\u201373","DOI":"10.1213\/ANE.0000000000006039"},{"key":"10.3238\/arztebl.m2026.0046_ref51","doi-asserted-by":"crossref","unstructured":"Barrett WJ, Kaucher KA, Orpet RE, et al.: Tranexamic acid in trauma: A joint position statement and resource document of NAEMSP, ACEP, and ACS-COT. J Trauma Acute Care Surg 2025; 99: 357\u201363","DOI":"10.1097\/TA.0000000000004727"},{"key":"10.3238\/arztebl.m2026.0046_ref52","doi-asserted-by":"crossref","unstructured":"Gruen DS, Brown JB, Guyette FX, et al.: Prehospital tranexamic acid is associated with a dose-dependent decrease in syndecan-1 after trauma: A secondary analysis of a prospective randomized trial. J Trauma Acute Care Surg 2023; 95: 642\u20138","DOI":"10.1097\/TA.0000000000003955"},{"key":"10.3238\/arztebl.m2026.0046_ref53","doi-asserted-by":"crossref","unstructured":"CRASH-2 Trial Collaborators, Roberts I, Shakur H, et al.: The importance of early treatment with tranexamic acid in bleeding trauma patients: An exploratory analysis of the CRASH-2 randomised controlled trial. Lancet 2011; 377: 1096\u2013101, 1101.e1\u20132","DOI":"10.1016\/S0140-6736(11)60278-X"},{"key":"10.3238\/arztebl.m2026.0046_ref54","doi-asserted-by":"crossref","unstructured":"Gayet-Ageron A, Prieto-Merino D, Ker K, et al.: Effect of treatment delay on the effectiveness and safety of antifibrinolytics in acute severe haemorrhage: A meta-analysis of individual patient-level data from 40 138 bleeding patients. Lancet 2018; 391: 125\u201332","DOI":"10.1016\/S0140-6736(17)32455-8"},{"key":"10.3238\/arztebl.m2026.0046_ref55","doi-asserted-by":"crossref","unstructured":"Sperry JL, Guyette FX, Brown JB, et al.: Prehospital plasma during air medical transport in trauma patients at risk for hemorrhagic shock. N Engl J Med 2018; 379: 315\u201326","DOI":"10.1056\/NEJMc1811315"},{"key":"10.3238\/arztebl.m2026.0046_ref56","doi-asserted-by":"crossref","unstructured":"Rowell SE, Meier EN, McKnight B, et al.: Effect of out-of-hospital tranexamic acid vs placebo on 6-month functional neurologic outcomes in patients with moderate or severe traumatic brain injury. JAMA 2020; 324: 961\u201374","DOI":"10.1001\/jama.2020.8958"},{"key":"10.3238\/arztebl.m2026.0046_ref57","doi-asserted-by":"crossref","unstructured":"Brito AM, Meizoso JP, Costantini TW: Research priorities in tranexamic acid after trauma: Secondary analysis of the National Trauma Research Action Plan. J Trauma Acute Care Surg 2024; 97: 566\u201371","DOI":"10.1097\/TA.0000000000004358"},{"key":"10.3238\/arztebl.m2026.0046_ref58","doi-asserted-by":"crossref","unstructured":"Vigneshwar NG, Moore EE, Moore HB, et al.: Precision medicine: Clinical tolerance to hyperfibrinolysis differs by shock and injury severity. Ann Surg 2022; 275: e605\u2013e7","DOI":"10.1097\/SLA.0000000000004548"},{"key":"10.3238\/arztebl.m2026.0046_ref59","doi-asserted-by":"crossref","unstructured":"Grassin-Delyle S, Theusinger OM, Albrecht R, et al.: Optimisation of the dosage of tranexamic acid in trauma patients with population pharmacokinetic analysis. Anaesthesia 2018; 73: 719\u201329","DOI":"10.1111\/anae.14184"},{"key":"10.3238\/arztebl.m2026.0046_ref60","doi-asserted-by":"crossref","unstructured":"Picetti R, Shakur-Still H, Medcalf RL, Standing JF, Roberts I: What concentration of tranexamic acid is needed to inhibit fibrinolysis? A systematic review of pharmacodynamics studies. Blood Coagul Fibrinolysis 2019; 30: 1\u201310","DOI":"10.1097\/MBC.0000000000000789"},{"key":"10.3238\/arztebl.m2026.0046_ref61","doi-asserted-by":"crossref","unstructured":"Henry DA, Carless PA, Moxey AJ, et al.: Anti-fibrinolytic use for minimising perioperative allogeneic blood transfusion. Cochrane Database Syst Rev 2007: CD001886","DOI":"10.1002\/14651858.CD001886.pub2"},{"key":"10.3238\/arztebl.m2026.0046_ref62","doi-asserted-by":"crossref","unstructured":"Hmidan Simsam M, Delorme L, Grimm D, et al.: Efficacy of high dose tranexamic acid (TXA) for hemorrhage: A systematic review and meta-analysis. Injury 2023; 54: 857\u201370","DOI":"10.1016\/j.injury.2022.12.029"},{"key":"10.3238\/arztebl.m2026.0046_ref63","unstructured":"National Institute for Health and Care Excellence (NICE): NICE guideline NG232. Head injury: assessment and early management. https:\/\/www.nice.org.uk\/guidance\/ng232 (last accessed on 3 February 2024)."},{"key":"10.3238\/arztebl.m2026.0046_ref64","doi-asserted-by":"crossref","unstructured":"Stitt G, Spinella PC, Bochicchio GV, Roberts I, Downes KJ, Zuppa AF: Population pharmacokinetic modelling and simulation of tranexamic acid in adult trauma patients. Br J Clin Pharmacol 2024; 90: 1932\u201341","DOI":"10.1111\/bcp.16075"},{"key":"10.3238\/arztebl.m2026.0046_ref65","doi-asserted-by":"crossref","unstructured":"Drew B, Auten JD, Cap AP, et al.: The use of tranexamic acid in tactical combat casualty care: TCCC proposed change 20\u201302. J Spec Oper Med 2020; 20: 36\u201343","DOI":"10.55460\/ZWV3-5CBW"},{"key":"10.3238\/arztebl.m2026.0046_ref66","doi-asserted-by":"crossref","unstructured":"Nakae R, Murai Y, Wada T, et al.: Hyperfibrinolysis and fibrinolysis shutdown in patients with traumatic brain injury. Sci Rep 2022; 12: 19107","DOI":"10.1038\/s41598-022-23912-4"},{"key":"10.3238\/arztebl.m2026.0046_ref67","doi-asserted-by":"crossref","unstructured":"Meizoso JP, Moore HB, Moore EE, et al.: Traumatic brain injury provokes low fibrinolytic activity in severely injured patients. J Trauma Acute Care Surg 2022; 93: 8\u201312","DOI":"10.1097\/TA.0000000000003559"},{"key":"10.3238\/arztebl.m2026.0046_ref68","doi-asserted-by":"crossref","unstructured":"Favors L, Harrell K, Miles V, et al.: Analysis of fibrinolytic shutdown in trauma patients with traumatic brain injury. Am J Surg 2024; 227: 72\u20136","DOI":"10.1016\/j.amjsurg.2023.09.034"},{"key":"10.3238\/arztebl.m2026.0046_ref69","doi-asserted-by":"crossref","unstructured":"Chang Y, Lai PC, Huang CY, et al.: Tranexamic acid in spontaneous intracerebral hemorrhage: A meta-analysis. Eur J Med Res 2025; 30: 133","DOI":"10.1186\/s40001-025-02385-x"},{"key":"10.3238\/arztebl.m2026.0046_ref70","doi-asserted-by":"crossref","unstructured":"Imai E, Ito H, Okano H, et al.: Efficacy and safety of tranexamic acid administration for subarachnoid hemorrhage: A systematic review and meta-analysis. Front Neurol 2025; 16: 1617817","DOI":"10.3389\/fneur.2025.1617817"},{"key":"10.3238\/arztebl.m2026.0046_ref71","doi-asserted-by":"crossref","unstructured":"Meer MM, Mumtaz M, Farrukh Z, Ahmed B: Efficacy and safety of tranexamic acid in traumatic brain injury: A systematic review and meta-analysis of randomized controlled trials. Cureus 2024; 16: e73781","DOI":"10.7759\/cureus.73781"},{"key":"10.3238\/arztebl.m2026.0046_ref72","doi-asserted-by":"crossref","unstructured":"Mahmood A, Needham K, Shakur-Still H, et al.: Effect of tranexamic acid on intracranial haemorrhage and infarction in patients with traumatic brain injury: A pre-planned substudy in a sample of CRASH-3 trial patients. Emerg Med J 2021; 38: 270\u20138","DOI":"10.1136\/emermed-2020-210424"},{"key":"10.3238\/arztebl.m2026.0046_ref73","doi-asserted-by":"crossref","unstructured":"Tjerkstra MA, Post R, Germans MR, et al.: Ultra-early and short-term tranexamic acid treatment in patients with good- and poor-grade aneurysmal subarachnoid hemorrhage. Neurology 2024; 102: e209169","DOI":"10.1212\/WNL.0000000000209169"},{"key":"10.3238\/arztebl.m2026.0046_ref74","doi-asserted-by":"crossref","unstructured":"Yeguiayan JM, Rosencher N, Freysz M: Tranexamic acid for trauma. Lancet 2010; 376: 1050; author reply 1050\u20131","DOI":"10.1016\/S0140-6736(10)61478-X"},{"key":"10.3238\/arztebl.m2026.0046_ref75","unstructured":"Arznei-telegramm: Tranexams\u00e4ure (Cyklokapron u.a.) nach Sch\u00e4del-Hirn-Trauma. a-t 2019; 50: 92."},{"key":"10.3238\/arztebl.m2026.0046_ref76","doi-asserted-by":"crossref","unstructured":"Lier H, Maegele M, Shander A: Tranexamic acid for acute hemorrhage: A narrative review of landmark studies and a critical reappraisal of its use over the last decade. Anesth Analg 2019; 129: 1574\u201384","DOI":"10.1213\/ANE.0000000000004389"},{"key":"10.3238\/arztebl.m2026.0046_ref77","doi-asserted-by":"crossref","unstructured":"Brito AMP, Schreiber MA, El Haddi J, Meier EN, Rowell SE: The effects of timing of prehospital tranexamic acid on outcomes after traumatic brain injury: Subanalysis of a randomized controlled trial. J Trauma Acute Care Surg 2023; 94: 86\u201392","DOI":"10.1097\/TA.0000000000003767"},{"key":"10.3238\/arztebl.m2026.0046_ref78","doi-asserted-by":"crossref","unstructured":"Wirtz MR, Schalkers DV, Goslings JC, Juffermans NP: The impact of blood product ratio and procoagulant therapy on the development of thromboembolic events in severely injured hemorrhaging trauma patients. Transfusion 2020; 60: 1873\u201382","DOI":"10.1111\/trf.15917"},{"key":"10.3238\/arztebl.m2026.0046_ref79","doi-asserted-by":"crossref","unstructured":"Polymeris AA, Karwacki GM, Siepen BM, et al.: Tranexamic acid for intracerebral hemorrhage in patients on non-vitamin K antagonist oral anticoagulants (TICH-NOAC): A multicenter, randomized, placebo-controlled, phase 2 trial. Stroke 2023; 54: 2223\u201334","DOI":"10.1161\/STROKEAHA.123.042866"},{"key":"10.3238\/arztebl.m2026.0046_ref80","doi-asserted-by":"crossref","unstructured":"Tsan SEH, Viknaswaran NL, Cheong CC, et al.: Prophylactic intravenous tranexamic acid and thromboembolism in non-cardiac surgery: A systematic review, meta-analysis and trial sequential analysis. Anaesthesia 2023; 78: 1153\u201361","DOI":"10.1111\/anae.16058"},{"key":"10.3238\/arztebl.m2026.0046_ref81","doi-asserted-by":"crossref","unstructured":"Utsumi S, Ohki S, Shime N: Efficacy of tranexamic acid in adult isolated traumatic brain injury: A multicenter retrospective study. Am J Emerg Med 2025; 95: 173\u20138","DOI":"10.1016\/j.ajem.2025.05.030"}],"container-title":["Deutsches \u00c4rzteblatt international"],"original-title":[],"link":[{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0046","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T06:22:11Z","timestamp":1781072531000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.aerzteblatt.de\/10.3238\/arztebl.m2026.0046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,12]]},"references-count":81,"URL":"https:\/\/doi.org\/10.3238\/arztebl.m2026.0046","relation":{},"ISSN":["1866-0452"],"issn-type":[{"value":"1866-0452","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,12]]}}}